- Home
- CNTX vs CRBU Comparison
CNTX vs CRBU Comparison
Compare CNTX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- CRBU
- Stock Information
- Founded
- CNTX 2015
- CRBU 2011
- Country
- CNTX United States
- CRBU United States
- Employees
- CNTX N/A
- CRBU N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- CNTX Health Care
- CRBU Health Care
- Exchange
- CNTX Nasdaq
- CRBU Nasdaq
- Market Cap
- CNTX 78.0M
- CRBU 93.0M
- IPO Year
- CNTX 2021
- CRBU 2021
- Fundamental
- Price
- CNTX $0.81
- CRBU $2.05
- Analyst Decision
- CNTX Strong Buy
- CRBU Strong Buy
- Analyst Count
- CNTX 5
- CRBU 4
- Target Price
- CNTX $5.50
- CRBU $8.50
- AVG Volume (30 Days)
- CNTX 193.2K
- CRBU 1.9M
- Earning Date
- CNTX 08-06-2025
- CRBU 08-05-2025
- Dividend Yield
- CNTX N/A
- CRBU N/A
- EPS Growth
- CNTX N/A
- CRBU N/A
- EPS
- CNTX N/A
- CRBU N/A
- Revenue
- CNTX N/A
- CRBU $9,918,000.00
- Revenue This Year
- CNTX N/A
- CRBU $9.52
- Revenue Next Year
- CNTX N/A
- CRBU N/A
- P/E Ratio
- CNTX N/A
- CRBU N/A
- Revenue Growth
- CNTX N/A
- CRBU N/A
- 52 Week Low
- CNTX $0.49
- CRBU $0.66
- 52 Week High
- CNTX $2.75
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- CNTX 57.85
- CRBU 58.45
- Support Level
- CNTX $0.82
- CRBU $1.90
- Resistance Level
- CNTX $0.88
- CRBU $2.66
- Average True Range (ATR)
- CNTX 0.07
- CRBU 0.22
- MACD
- CNTX 0.00
- CRBU -0.01
- Stochastic Oscillator
- CNTX 42.87
- CRBU 42.18
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.